MedTrace Logo

Registry on Augmented Antithrombotic Treatment Regimens for Patients With Arterial Thrombotic APS

NCT05646394 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2025-12-09

No results posted yet for this study

Summary

The goal of this registry is to gather more information on the efficacy and safety of various antithrombotic regimens. The registry collects data on patients with antiphospholipid syndrome and an arterial event within the past 12 months, on treatment with either A) a VKA with therapeutic range, INR 2.0-3.0 plus low-dose aspirin (75-100 mg daily), B) a VKA alone with therapeutic range, INR 2.0-3.0, C) a VKA with therapeutic range, INR 3.0-4.0, or D) with a dual antiplatelet regimen. The follow-up is 2 years.

Conditions

  • Antiphospholipid Syndrome
  • Arterial Thrombosis

Interventions

DRUG

Dual antiplatelet therapy

Aspirin plus any of clopidogrel, ticagrelor or prasugrel

DRUG

Combined antithrombotic therapy

Combination of a vitamin K antagonist, such as warfarin, acenocoumarol, phenprocoumon, phenindione etc, with low-dose aspirin.

DRUG

Vitamin K antagonist standard intensity

vitamin K antagonist, such as warfarin, acenocoumarol, phenprocoumon, phenindione etc, with therapeutic range, international normalized ratio 2.0-3.0

DRUG

Vitamin K antagonist high intensity

vitamin K antagonist, such as warfarin, acenocoumarol, phenprocoumon, phenindione etc, with therapeutic range, international normalized ratio 3.0-4.0

Sponsors & Collaborators

  • International Society on Thrombosis and Haemostasis

    collaborator UNKNOWN

  • McMaster University

    lead OTHER

Principal Investigators

  • Cary Clark · International Society on Thrombosis and Haemostasis

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-01
Primary Completion
2029-07-31
Completion
2029-12-31

Countries

  • Argentina
  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05646394 on ClinicalTrials.gov